AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

Search

Indivior PLC

Deschisă

984.5 -2.91

Rezumat

Modificarea prețului

24h

Curent

Minim

971

Maxim

1014

Indicatori cheie

By Trading Economics

Venit

-19M

47M

Vânzări

-33M

266M

P/E

Medie Sector

330

50.291

EPS

0.41

Marjă de profit

17.669

Angajați

1,030

EBITDA

-30M

76M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+1.66% upside

Dividende

By Dow Jones

Următoarele câștiguri

24 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

504M

1.3B

Deschiderea anterioară

987.41

Închiderea anterioară

984.5

Indivior PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 iun. 2025, 23:49 UTC

Câștiguri

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 iun. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 iun. 2025, 21:30 UTC

Câștiguri

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Câștiguri

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 iun. 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 iun. 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 iun. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 iun. 2025, 23:33 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 iun. 2025, 23:30 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 iun. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 iun. 2025, 23:19 UTC

Achiziții, Fuziuni, Preluări

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 iun. 2025, 22:06 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:15 UTC

Câștiguri

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 iun. 2025, 21:07 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 iun. 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 20:52 UTC

Câștiguri

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 iun. 2025, 20:51 UTC

Câștiguri

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Indivior PLC Așteptări

Obiectiv de preț

By TipRanks

1.66% sus

Prognoză pe 12 luni

Medie 1,024.7 GBX  1.66%

Maxim 1,100 GBX

Minim 949.403 GBX

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIndivior PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.